Interestingly, a recent work shows that neutrophils with high expression in Ly6E not only act as a biomarker but also function as an immunomodulator sensitizing melanoma-resistant tumors to anti-PD1 therapy, in part, by creating an environment permissive to CD8+ T cell activation through secretion of known activating factors such as IL-12b [44,45]. This evidence concerns the gene CD8A and melanoma.